Related Experiment Video

Updated: May 24, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?

Axel Bex1, Tamara Etto, Florry Vyth-Dreese

  • 1Division of Surgical Oncology, Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. a.bex@nki.nl

Current Oncology Reports
|February 25, 2012
PubMed

Insights

Targeted therapy for metastatic clear-cell renal cell carcinoma (RCC) shows promise by modulating immune responses. Further research into these mechanisms could lead to improved drug development and better treatment outcomes for kidney cancer.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Metastatic clear-cell renal cell carcinoma (RCC) treatment has improved with targeted agents.
  • Current therapies, including vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI), have limitations, with rare complete responses and no curative effect.
  • A plateau in efficacy for the latest generation of VEGFR TKIs has been observed.

Purpose of the Study:

  • To provide insight into targeted therapy-induced changes in the immunological microenvironment of RCC.
  • To summarize existing evidence on the immunomodulatory effects of targeted agents in RCC.
  • To discuss potential therapeutic implications of these immunomodulatory changes for drug development.

Main Methods:

  • This review synthesizes current research findings.
  • It focuses on the interplay between targeted agents and the immune system in RCC.
  • Evidence from preclinical and clinical studies is summarized.

Main Results:

  • Targeted agents, particularly VEGFR TKIs, can modulate immune responses within the RCC tumor microenvironment.
  • Understanding these immunomodulatory effects is crucial for deciphering RCC's escape from anti-tumor immunity.
  • Recent data highlight the role of targeted agents in influencing the immune landscape.

Conclusions:

  • Targeted therapies impact the immune microenvironment in clear-cell RCC.
  • Further understanding of these interactions can inform the development of novel therapeutic strategies.
  • Modulating the immune response alongside targeted therapy may enhance treatment efficacy for advanced kidney cancer.

More Related Videos

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview